Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.

Schuette W, Schneider CP, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke MHU, Hoeffken G, Kortsik C, Reck M.

Lung Cancer (Auckl). 2017 Nov 6;8:217-229. doi: 10.2147/LCTT.S142972. eCollection 2017.

2.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE.

J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.

PMID:
29023213
3.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

4.

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

Goldman JW, Crino L, Vokes EE, Holgado E, Reckamp K, Pluzanski A, Spigel D, Kohlhaeufl M, Garassino M, Chow LQ, Gettinger S, Gerber DE, Havel L, Ramalingam SS, Dy GK, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Lopes G.

J Thorac Oncol. 2016 Oct;11(10S):S238-S239. doi: 10.1016/j.jtho.2016.08.107. Epub 2016 Sep 22. No abstract available.

5.

Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.

Bonella F, Kreuter M, Hagmeyer L, Neurohr C, Keller C, Kohlhaeufl MJ, Müller-Quernheim J, Milger K, Prasse A; German Nintedanib Compassionate Use Consortium.

Respiration. 2016;92(2):98-106. doi: 10.1159/000448288. Epub 2016 Aug 20.

6.

Treatment of severe advanced emphysema with volume reduction using lung sealant: a case report of 2 patients.

Falkenstern-Ge RF, Ingerl H, Kohlhaeufl M.

J Bronchology Interv Pulmonol. 2013 Jan;20(1):58-62. doi: 10.1097/LBR.0b013e3182824782.

PMID:
23328146
7.

MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.

Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, Kohlhaeufl M.

Lung Cancer. 2012 Jun;76(3):373-9. doi: 10.1016/j.lungcan.2011.11.020. Epub 2012 Jan 10.

PMID:
22236866
8.

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: 7-year follow-up of a rare clinicopathologic syndrome.

Falkenstern-Ge RF, Kimmich M, Friedel G, Tannapfel A, Neumann V, Kohlhaeufl M.

J Cancer Res Clin Oncol. 2011 Oct;137(10):1495-8. doi: 10.1007/s00432-011-1015-z. Epub 2011 Aug 9.

PMID:
21826622
9.

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.

Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ; Mpex 204 Study Group.

Am J Respir Crit Care Med. 2011 Jun 1;183(11):1510-6. doi: 10.1164/rccm.201008-1293OC. Epub 2011 Feb 25.

PMID:
21471106
10.

Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.

Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, Pfannenberg C, Al-Kamash F, Walles T, Aebert H, Kyriss T, Veit S, Kimmich M, Bamberg M, Kohlhaeufl M, Steger V, Hehr T.

J Clin Oncol. 2010 Feb 20;28(6):942-8. doi: 10.1200/JCO.2008.21.7810. Epub 2010 Jan 25.

PMID:
20100967
11.

Clinical perspectives on pulmonary systemic and macromolecular delivery.

Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R.

Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):996-1008. Epub 2006 Aug 12. Review.

PMID:
16996638
12.

Comparison of clearance of particles inhaled with bolus and extremely slow inhalation techniques.

Svartengren M, Sommerer K, Scheuch G, Kohlhaeufl M, Heyder J, Falk R, Bergmann R, Hofmann W, Bailey M, Philipson K, Camner P.

Exp Lung Res. 2001 Jun;27(4):367-86.

PMID:
11400862

Supplemental Content

Loading ...
Support Center